Guerbet (GBT) Stock Overview
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
GBT Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Guerbet SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €13.12 |
52 Week High | €39.35 |
52 Week Low | €12.72 |
Beta | 0.79 |
1 Month Change | -37.82% |
3 Month Change | -38.11% |
1 Year Change | -64.73% |
3 Year Change | -19.01% |
5 Year Change | -52.20% |
Change since IPO | 32.07% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Guerbet SA's (EPA:GBT) Tunnel And Push Stock Down 32%
Sep 17The Returns At Guerbet (EPA:GBT) Aren't Growing
Aug 02Not Many Are Piling Into Guerbet SA (EPA:GBT) Stock Yet As It Plummets 27%
Apr 09Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%
Nov 16Is Guerbet (EPA:GBT) Using Too Much Debt?
Apr 27Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce
Feb 29Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture
Feb 11Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch
Jan 15The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Jul 22Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price
Jul 27Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report
Mar 28Is Guerbet (EPA:GBT) A Risky Investment?
Oct 25The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence
Sep 23Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?
May 27We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt
May 04Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?
Apr 05Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 19What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?
Mar 01When Should You Buy Guerbet SA (EPA:GBT)?
Feb 10How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Jan 13Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?
Dec 23We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential
Dec 11Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?
Nov 27Shareholder Returns
GBT | FR Medical Equipment | FR Market | |
---|---|---|---|
7D | -7.0% | -2.9% | -1.1% |
1Y | -64.7% | 24.4% | -1.1% |
Return vs Industry: GBT underperformed the French Medical Equipment industry which returned 24.4% over the past year.
Return vs Market: GBT underperformed the French Market which returned -1.1% over the past year.
Price Volatility
GBT volatility | |
---|---|
GBT Average Weekly Movement | 8.2% |
Medical Equipment Industry Average Movement | 5.2% |
Market Average Movement | 4.6% |
10% most volatile stocks in FR Market | 10.3% |
10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: GBT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: GBT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1926 | 2,842 | Jerome Estampes | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as OptiProtect services.
Guerbet SA Fundamentals Summary
GBT fundamental statistics | |
---|---|
Market cap | €162.08m |
Earnings (TTM) | €7.74m |
Revenue (TTM) | €820.92m |
Is GBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GBT income statement (TTM) | |
---|---|
Revenue | €820.92m |
Cost of Revenue | €208.89m |
Gross Profit | €612.03m |
Other Expenses | €604.29m |
Earnings | €7.74m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | 0.61 |
Gross Margin | 74.55% |
Net Profit Margin | 0.94% |
Debt/Equity Ratio | 0% |
How did GBT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/09/26 17:54 |
End of Day Share Price | 2025/09/26 00:00 |
Earnings | 2025/06/30 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guerbet SA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Arnaud Cadart | CIC Market Solutions (ESN) |
Guillaume Cuvillier | Gilbert Dupont |
Clement Vignard | Gilbert Dupont |